Evidence map›Paper›PMID 41979819›Full record

ArticleDrug safety2026

Sexual Dysfunction with Antipsychotics: Emerging Clues from a Disproportionality Analysis of the World Health Organization VigiBase.

Efstathios Pavlidis, Spyridon Siafis, Elena Arzenton, Salvatore Crisafulli, Emanuel Raschi, Ugo Moretti, Andrea M Isidori, Emmanuele A Jannini, Gianluca Trifirò, Erich Seifritz and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Efstathios PavlidisPsychiatric University Hospital Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland.
Spyridon SiafisTUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
Elena ArzentonSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Salvatore CrisafulliSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Emanuel RaschiPharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Ugo MorettiSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Andrea M IsidoriDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Emmanuele A JanniniChair of Endocrinology and Medical Sexology (ENDOSEX), Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Gianluca TrifiròSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Erich SeifritzPsychiatric University Hospital Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland.
Corrado BarbuiDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
Chiara Gastaldon *Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
Georgios Schoretsanitis *Psychiatric University Hospital Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland. george.schor@gmail.com.ORCID http://orcid.org/0000-0002-3851-4117

Funding

European Union - Next Generation EU, Mission 4, Component 1 B53D23030830001
6 · The paper itself

Abstract

introductionAntipsychotic-associated sexual adverse drug reactions (ADRs) are well known in clinical practice, although efforts to understand differences between antipsychotics and distinct types of sexual ADRs are limited.

objectiveThe aim of this study was to assess and prioritize the profile of each antipsychotic regarding sexual ADRs reporting, and to account for potential confounders.

methodsWe used VigiBase

resultsWe included 5195 cases of antipsychotic-related sexual ADRs (43.1% serious, median time to onset of 61 days, 36.1% physician-reported). Several SDRs emerged in males (erectile dysfunction [3487 reports; ROR 2.49, 95% CI 2.40-2.57]; priapism [2372 reports; ROR 15.55, 95% CI 14.82-16.32]) and females (decreased libido [373 reports; ROR 1.61, 95% CI 1.46-1.79]) for all antipsychotic classes, except for muscarinic antagonists in females (ROR 0.64, 95% CI 0.55-0.73; IC - 0.65, 95% CI - 0.86 to - 0.45). In both sexes, the highest number of reports were for risperidone, aripiprazole and olanzapine. The SDRs disappeared in the sensitivity analysis including only non-serious cases and cases with co-reported hyperprolactinemia. Sexual ADRs for all antipsychotics were classified as of moderate priority, with the exception of fluspirilene (low priority).

conclusionsNotwithstanding limitations, including inability to infer causality, these findings raise the hypothesis that sexual ADRs could be a class effect of antipsychotics, yet possibly reversible, in both women and men. REGISTRATION: The protocol is registered to the Open Science Framework: https://osf.io/96eq7 .

Indexed as

Adverse Drug Reaction Reporting SystemsAntipsychotic AgentsSexual Dysfunction, PhysiologicalAdultAgedBayes TheoremFemaleHumansMaleMiddle AgedWorld Health OrganizationYoung AdultAntipsychotic Agents

Identifiers

PMID41979819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.